Susbind

Ongoing projects, Horizon 2020

The SUSBIND Consortium develops, produces and tests bio-based binders as an alternative to fossil-based binders currently used for wood-based panel board in furniture mass products.

SUSBIND is a European project in the field of bioeconomy, research and innovation that brings together 11 Partners from 6 EU countries from research and industry.  The partners from Austria, Germany, the Netherlands, Spain and Portugal consist of big industry and small and medium-sized (SMEs) companies, university and other research centres.

Client

Susbind

EC Contribution

€4.1 million

Start date

01/05/2018

Duration

48 months

Project details

[dkpdf-button]

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

WEBSITE & SOCIAL MEDIA

The challenge

Antimicrobial resistance in livestock is a public health threat due to the risk of zoonotic transmission to humans and its negative consequences on animal health and welfare when diseases cannot be treated. Antimicrobial treatment options for pigs are increasingly limited because of planned restrictions in the use of colistin and zinc, two current choices for treatment of post-weaning diarrhoea.

The solution

AVANT is a multi-actor inter-sectorial project aimed at developing alternatives to antimicrobials for the management of bacterial infections in pigs, especially diarrhoea during the weaning period, as the major indication for antimicrobial use in livestock in Europe. During pre-clinical studies, efficacy, toxicity, and mode of action of these interventions is tested, and their dosage and formulation optimized. The results and a survey for veterinarian-, farmer- and consumers perception of antimicrobial alternatives, will be used together with legal and economic considerations to select three interventions for large-scale farm trials, assessing clinical efficacy and impact on antimicrobial use.

The main impacts

The AVANT portfolio comprises a variety of alternatives for treatment or prevention of diarrhoea and/or respiratory infections, namely:

  • Gut-stabilizing interventions based on a symbiotic (pre- and probiotic) product and faecal microbiota transplantation
  • Novel veterinary medicinal products containing bacteriophages and polymers for targeted treatment of enterotoxigenic coli infections
  • Immuno-stimulating injectable and feed additive products
  • Alternative feeding strategies targeting sows and piglets

All steps are supported by regulatory advice for quick market entry post-project. Generated and existing data on antimicrobial use, pig demographics and projected consumption of pork, will be used in mathematical modelling to estimate the reduction in antimicrobial use that could be achieved by 2030, if the AVANT alternatives were widely adopted in pig production.

The funding

AVANT has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 862829.

CORDIS: https://cordis.europa.eu/project/rcn/225153/factsheet/en

The challenge

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

The solution

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

The main impacts

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

The funding

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.